$CVS
CVS Health Corp

2021 Q4 Form 10-Q Financial Statement

#000006480321000034 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $76.60B $73.79B $67.06B
YoY Change 10.14% 10.05% 3.47%
Cost Of Revenue $46.38B $45.01B $40.94B
YoY Change 9.25% 9.94% 1.24%
Gross Profit $30.23B $28.78B $26.12B
YoY Change 11.53% 10.21% 7.15%
Gross Profit Margin 39.46% 39.0% 38.95%
Selling, General & Admin $9.190B $8.685B
YoY Change 5.81% 1.58%
% of Gross Profit 31.93% 33.26%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $26.61B $25.27B $8.471B
YoY Change 8.87% 198.32% -1.44%
Operating Profit $3.618B $3.061B $3.249B
YoY Change 35.91% -5.79% 10.96%
Interest Expense -$608.0M $602.0M $731.0M
YoY Change -10.32% -17.65% -2.14%
% of Operating Profit -16.8% 19.67% 22.5%
Other Income/Expense, Net $38.00M $49.00M $54.00M
YoY Change -28.3% -9.26% 74.19%
Pretax Income $1.570B $2.145B $1.806B
YoY Change 28.16% 18.77% -15.33%
Income Tax $274.0M $558.0M $587.0M
% Of Pretax Income 17.45% 26.01% 32.5%
Net Earnings $1.306B $1.598B $1.224B
YoY Change 34.22% 30.56% -20.0%
Net Earnings / Revenue 1.7% 2.17% 1.83%
Basic Earnings Per Share $1.21 $0.93
Diluted Earnings Per Share $976.1K $1.20 $0.93
COMMON SHARES
Basic Shares Outstanding 1.320B shares 1.321B shares 1.310B shares
Diluted Shares Outstanding 1.329B shares 1.315B shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.53B $12.84B $12.09B
YoY Change 15.4% 6.24% 60.58%
Cash & Equivalents $9.408B $9.826B $9.256B
Short-Term Investments $3.117B $3.015B $2.831B
Other Short-Term Assets $5.292B $5.319B $5.830B
YoY Change 0.28% -8.77% 20.43%
Inventory $17.76B $17.40B $17.48B
Prepaid Expenses
Receivables $24.43B $25.28B $23.82B
Other Receivables $3.389B $2.767B $3.171B
Total Short-Term Assets $60.01B $60.84B $59.21B
YoY Change 6.46% 2.75% 22.88%
LONG-TERM ASSETS
Property, Plant & Equipment $12.90B $12.77B $12.35B
YoY Change 2.3% 3.42% 5.99%
Goodwill $79.12B $79.12B $79.58B
YoY Change -0.54% -0.58% 0.04%
Intangibles $29.03B $29.55B $31.70B
YoY Change -6.79% -6.79% -5.82%
Long-Term Investments $23.03B $22.37B $20.22B
YoY Change 10.63% 10.65% 16.57%
Other Assets $4.714B $4.694B $4.569B
YoY Change 1.95% 2.74% 4.2%
Total Long-Term Assets $173.0B $174.0B $173.7B
YoY Change -0.78% 0.21% 1.02%
TOTAL ASSETS
Total Short-Term Assets $60.01B $60.84B $59.21B
Total Long-Term Assets $173.0B $174.0B $173.7B
Total Assets $233.0B $234.9B $232.9B
YoY Change 0.99% 0.86% 5.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.68B $39.47B $34.99B
YoY Change 10.94% 12.79% 18.4%
Accrued Expenses $17.67B $16.14B $14.33B
YoY Change 24.06% 12.64% 23.37%
Deferred Revenue $87.00M $78.00M $75.00M
YoY Change 22.54% 4.0% 4.17%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $4.205B $1.561B $5.443B
YoY Change -22.7% -71.32% 44.07%
Total Short-Term Liabilities $67.81B $64.71B $62.04B
YoY Change 9.34% 4.3% 18.08%
LONG-TERM LIABILITIES
Long-Term Debt $51.97B $56.83B $61.55B
YoY Change -12.22% -7.67% -4.13%
Other Long-Term Liabilities $1.904B $2.310B $2.520B
YoY Change -19.01% -8.33% 15.7%
Total Long-Term Liabilities $1.904B $2.310B $2.520B
YoY Change -19.01% -8.33% -96.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.81B $64.71B $62.04B
Total Long-Term Liabilities $1.904B $2.310B $2.520B
Total Liabilities $157.6B $160.3B $163.8B
YoY Change -2.11% -2.14% 4.2%
SHAREHOLDERS EQUITY
Retained Earnings $54.91B $54.26B $49.33B
YoY Change 10.61% 10.01% 12.07%
Common Stock $17.00M $17.00M $17.00M
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $28.17B $28.17B $28.16B
YoY Change -0.02% 0.01% -0.15%
Treasury Stock Shares 422.0M shares 422.0M shares 423.0M shares
Shareholders Equity $75.08B $74.31B $68.81B
YoY Change
Total Liabilities & Shareholders Equity $233.0B $234.9B $232.9B
YoY Change 0.99% 0.86% 5.81%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $1.306B $1.598B $1.224B
YoY Change 34.22% 30.56% -20.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $4.005B $5.521B $1.874B
YoY Change 12.28% 194.61% -36.0%
INVESTING ACTIVITIES
Capital Expenditures -$597.0M -$608.0M -$534.0M
YoY Change -16.27% 13.86% -11.15%
Acquisitions
YoY Change
Other Investing Activities -$843.0M -$239.0M -$836.0M
YoY Change 61.8% -71.41% 266.67%
Cash From Investing Activities -$1.440B -$847.0M -$1.370B
YoY Change 16.69% -38.18% 65.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.831B -1.967B -6.117B
YoY Change -24.2% -67.84% 106.1%
NET CHANGE
Cash From Operating Activities 4.005B 5.521B 1.874B
Cash From Investing Activities -1.440B -847.0M -1.370B
Cash From Financing Activities -2.831B -1.967B -6.117B
Net Change In Cash -266.0M 2.707B -5.613B
YoY Change -81.03% -148.23% 545.91%
FREE CASH FLOW
Cash From Operating Activities $4.005B $5.521B $1.874B
Capital Expenditures -$597.0M -$608.0M -$534.0M
Free Cash Flow $4.602B $6.129B $2.408B
YoY Change 7.52% 154.53% -31.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-01011
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive,
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket,
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1320058657 shares
CY2021Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
18984000000 USD
CY2020Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
17182000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
56927000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
51749000000 USD
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
832000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
CY2021Q3 us-gaap Revenues
Revenues
73794000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
us-gaap Revenues
Revenues
215507000000 USD
us-gaap Revenues
Revenues
199152000000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45011000000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40940000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
129425000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
121529000000 USD
CY2021Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
16081000000 USD
CY2020Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
14396000000 USD
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
47686000000 USD
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
40534000000 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q3 cvs Operating Expenses Excluding Goodwill Impairments
OperatingExpensesExcludingGoodwillImpairments
9210000000 USD
CY2020Q3 cvs Operating Expenses Excluding Goodwill Impairments
OperatingExpensesExcludingGoodwillImpairments
8471000000 USD
cvs Operating Expenses Excluding Goodwill Impairments
OperatingExpensesExcludingGoodwillImpairments
27001000000 USD
cvs Operating Expenses Excluding Goodwill Impairments
OperatingExpensesExcludingGoodwillImpairments
25702000000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
70733000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
63807000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
204543000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
187765000000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3061000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3249000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
10964000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11387000000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
602000000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
731000000 USD
us-gaap Interest Expense
InterestExpense
1895000000 USD
us-gaap Interest Expense
InterestExpense
2229000000 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
144000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
153000000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2145000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1806000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8850000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8545000000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
558000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
587000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2248000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2328000000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
us-gaap Profit Loss
ProfitLoss
6602000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11000000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
1598000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1224000000 USD
us-gaap Net Income Loss
NetIncomeLoss
6604000000 USD
us-gaap Net Income Loss
NetIncomeLoss
6206000000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.21
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.74
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1321000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1310000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1318000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1308000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1329000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1326000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
us-gaap Profit Loss
ProfitLoss
6602000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-73000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
44000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-310000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
257000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-22000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
236000000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1494000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1261000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6265000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6453000000 USD
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-11000000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1505000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1266000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6267000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6442000000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9826000000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7854000000 USD
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
3015000000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25283000000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21742000000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
17399000000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
18496000000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5319000000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5277000000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
60842000000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
56369000000 USD
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
22370000000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
20812000000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12771000000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12606000000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20462000000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20729000000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
79121000000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
79552000000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29545000000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31142000000 USD
CY2021Q3 us-gaap Separate Account Assets
SeparateAccountAssets
5086000000 USD
CY2020Q4 us-gaap Separate Account Assets
SeparateAccountAssets
4881000000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4694000000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4624000000 USD
CY2021Q3 us-gaap Assets
Assets
234891000000 USD
CY2020Q4 us-gaap Assets
Assets
230715000000 USD
CY2021Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
12696000000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
11138000000 USD
CY2021Q3 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
17895000000 USD
CY2020Q4 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
15795000000 USD
CY2021Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
8877000000 USD
CY2020Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
7936000000 USD
CY2021Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
4444000000 USD
CY2020Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
4270000000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16140000000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14243000000 USD
CY2021Q3 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1287000000 USD
CY2020Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1557000000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1809000000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1638000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1561000000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
5440000000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
64709000000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62017000000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18456000000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18757000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
56832000000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59207000000 USD
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6329000000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6794000000 USD
CY2021Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
5086000000 USD
CY2020Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
4881000000 USD
CY2021Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
6551000000 USD
CY2020Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
7007000000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2310000000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
160273000000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2351000000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
161014000000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1743000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1321000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1733000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1310000000 shares
CY2021Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
47133000000 USD
CY2020Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
46513000000 USD
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
422000000 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
423000000 shares
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
28166000000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
28178000000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
54264000000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
49640000000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1077000000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1414000000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
74308000000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
69389000000 USD
CY2021Q3 us-gaap Minority Interest
MinorityInterest
310000000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
312000000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74618000000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69701000000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234891000000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230715000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
209104000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
195554000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
122129000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
116590000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
46965000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
40221000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
21840000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
22185000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
582000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
622000000 USD
us-gaap Interest Paid Net
InterestPaidNet
2095000000 USD
us-gaap Interest Paid Net
InterestPaidNet
2517000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2397000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2365000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12298000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5559000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3790000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
7417000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6377000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1923000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1724000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
135000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
828000000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
834000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-95000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3821000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4300000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
987000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7919000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7823000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10493000000 USD
us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
0 USD
us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
7000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1965000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1980000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
249000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
161000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
75000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-3000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8525000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4420000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1914000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3578000000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8130000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5954000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10044000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9532000000 USD
us-gaap Profit Loss
ProfitLoss
6602000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3397000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3302000000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
346000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
288000000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
271000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-363000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-645000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-25000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3504000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3564000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1097000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-45000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
32000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
211000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3973000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3495000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
348000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
-474000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1884000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2730000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14260000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12298000000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69701000000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2224000000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-392000000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000000 USD
CY2021Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
76000000 USD
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
660000000 USD
CY2021Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
1000000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71164000000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
2791000000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
148000000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
268000000 USD
CY2021Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
150000000 USD
CY2021Q2 us-gaap Dividends Common Stock
DividendsCommonStock
655000000 USD
CY2021Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-1000000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73565000000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
1587000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
138000000 USD
CY2021Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
86000000 USD
CY2021Q3 us-gaap Dividends Common Stock
DividendsCommonStock
665000000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 Segment
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74618000000 USD
CY2021Q3 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q4 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2021Q2 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2021Q1 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2021Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2021Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2021Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64170000000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
2012000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-332000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000000 USD
CY2020Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
53000000 USD
CY2020Q1 us-gaap Dividends Common Stock
DividendsCommonStock
657000000 USD
CY2020Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
23000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65474000000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
2986000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
526000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000000 USD
CY2020Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
53000000 USD
CY2020Q2 us-gaap Dividends Common Stock
DividendsCommonStock
662000000 USD
CY2020Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-12000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68355000000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000000 USD
CY2020Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
71000000 USD
CY2020Q3 us-gaap Dividends Common Stock
DividendsCommonStock
664000000 USD
CY2020Q3 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-23000000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69112000000 USD
CY2020Q1 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q2 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q3 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2019Q4 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2021Q3 cvs Numberof Pharmacy Plan Members
NumberofPharmacyPlanMembers
110000000 people
CY2021Q3 cvs Numberof Patients Servedper Year
NumberofPatientsServedperYear
1000000 patient
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9826000000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7854000000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
218000000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
276000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10044000000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8130000000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8398000000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7101000000 USD
CY2021Q3 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
11727000000 USD
CY2020Q4 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
9815000000 USD
CY2021Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2391000000 USD
CY2020Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2628000000 USD
CY2021Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2767000000 USD
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2198000000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25283000000 USD
CY2020 cvs Payments To Health Insurer Fee
PaymentsToHealthInsurerFee
1000000000 USD
cvs Health Insurer Fee
HealthInsurerFee
774000000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21742000000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
364000000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
358000000 USD
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 USD
CY2021Q3 us-gaap Revenues
Revenues
73794000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
832000000 USD
us-gaap Revenues
Revenues
215507000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
us-gaap Revenues
Revenues
199152000000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8398000000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7101000000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
71000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
71000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
286000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
266000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
279000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
264000000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78000000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
75000000 USD
CY2021Q3 cvs Health Insurer Fee
HealthInsurerFee
0 USD
cvs Health Insurer Fee
HealthInsurerFee
0 USD
CY2020Q3 cvs Health Insurer Fee
HealthInsurerFee
255000000 USD
CY2021Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
16000000 USD
CY2020Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
5000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
35000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
28000000 USD
CY2021Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
20000000 USD
CY2020Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
15000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
57000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
58000000 USD
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
3015000000 USD
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
22370000000 USD
CY2021Q3 us-gaap Investments
Investments
25385000000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000000 USD
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
20812000000 USD
CY2020Q4 us-gaap Investments
Investments
23812000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
21317000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1312000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22574000000 USD
CY2020Q4 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
19396000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1803000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21188000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet
1056000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1071000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet
7123000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
7390000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet
4492000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4718000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net
DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet
4190000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
4855000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
21317000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22574000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
2243 security
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
4239000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
49000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
822000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
100 security
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
151000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
6000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
2343 security
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
4390000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
55000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
468 security
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
869000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
10000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
59 security
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
46000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
527 security
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
915000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
11000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
22000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
0 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
1270000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
11000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
949000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
17000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
605000000 USD
CY2021Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
12000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
4390000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
55000000 USD
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
279000000 USD
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
203000000 USD
CY2021Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
3000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
550000000 USD
CY2021Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 USD
CY2020Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
8000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
28000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
25000000 USD
CY2021Q3 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
268000000 USD
CY2020Q3 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
195000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
794000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
525000000 USD
CY2021Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-22000000 USD
CY2020Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
9000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
38000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
25000000 USD
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
246000000 USD
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
204000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
832000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
550000000 USD
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
35000000 USD
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
CY2021Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
CY2020Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 USD
CY2020Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
2000000 USD
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
4000000 USD
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
44000000 USD
CY2021Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
668000000 USD
CY2020Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
905000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2935000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2324000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
19000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
17000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
61000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
60000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
3000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
12000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
59000000 USD
CY2021Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
6600000000 USD
CY2020Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
6100000000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
79552000000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
CY2021Q3 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
6800000000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
79121000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the nine months ended September 30, 2021 and 2020 in the table above exclude (i) $1 million and $1 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $45 million and $31 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets and (iii) $168 million and $173 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets.</span></div>
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1207000000 USD
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1083000000 USD
CY2021Q3 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
58987000000 USD
CY2020Q4 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
65318000000 USD
CY2021Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
224000000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
238000000 USD
CY2021Q3 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
818000000 USD
CY2020Q4 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
909000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
58393000000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
64647000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1561000000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
5440000000 USD
CY2021Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
56832000000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59207000000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-337000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
236000000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16000000 shares
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1598000000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1224000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6604000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6206000000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1321000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1310000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1318000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1308000000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8000000 shares
CY2012 cvs Loss Contingency Audit Methodology Sample Size
LossContingencyAuditMethodologySampleSize
200 member
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1329000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1326000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.21
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.74
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
CY2021Q3 cvs Guarantor Obligations Numberof Leases
GuarantorObligationsNumberofLeases
72 store
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 Segment
CY2021Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
73548000000 USD
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
246000000 USD
CY2021Q3 us-gaap Revenues
Revenues
73794000000 USD
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 USD
CY2020Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
66852000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
CY2020Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3622000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
214675000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
832000000 USD
us-gaap Revenues
Revenues
215507000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
198602000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
us-gaap Revenues
Revenues
199152000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13063000000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3061000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3249000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
10964000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11387000000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
561000000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
587000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1730000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1751000000 USD
CY2021Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
20000000 USD
CY2020Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
57000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
101000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
196000000 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
431000000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
0 USD
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
61000000 USD
CY2020Q3 cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
271000000 USD
cvs Business Combination Purchase Price Adjustment Outside Of Measurement Period
BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod
271000000 USD
CY2021Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4073000000 USD
CY2020Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3622000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13165000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13063000000 USD

Files In Submission

Name View Source Status
0000064803-21-000034-index-headers.html Edgar Link pending
0000064803-21-000034-index.html Edgar Link pending
0000064803-21-000034.txt Edgar Link pending
0000064803-21-000034-xbrl.zip Edgar Link pending
a09302021ex151.htm Edgar Link pending
a09302021ex311.htm Edgar Link pending
a09302021ex312.htm Edgar Link pending
a09302021ex321.htm Edgar Link pending
a09302021ex322.htm Edgar Link pending
cvs-20210930.htm Edgar Link pending
cvs-20210930.xsd Edgar Link pending
cvs-20210930_cal.xml Edgar Link unprocessable
cvs-20210930_def.xml Edgar Link unprocessable
cvs-20210930_g1.jpg Edgar Link pending
cvs-20210930_htm.xml Edgar Link completed
cvs-20210930_lab.xml Edgar Link unprocessable
cvs-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending